Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kimberly-Clark Enters $3 Bil. Glove Market Via $850 Mil. Safeskin Buy

This article was originally published in The Gray Sheet

Executive Summary

Acquisition of disposable medical glove maker Safeskin marks Kimberly-Clark's entrance into the $3 bil. worldwide latex and synthetic glove market and will boost sales of the firm's professional health care segment to approximately $950 mil. in 2000.

You may also be interested in...



Urologix' Building Momentum, New COO Help Boost Stock 63% In November

Continued momentum in sales of Urologix' Targis microwave catheter-based system for treatment of benign prostatic hyperplasia and procedure kit revenues, as well as growing acceptance of a "per-procedure" marketing strategy and strong additions to top management, helped Urologix stock jump 62.7% in November. The issue gained 2 points to close at 5-3/16

Urologix' Building Momentum, New COO Help Boost Stock 63% In November

Continued momentum in sales of Urologix' Targis microwave catheter-based system for treatment of benign prostatic hyperplasia and procedure kit revenues, as well as growing acceptance of a "per-procedure" marketing strategy and strong additions to top management, helped Urologix stock jump 62.7% in November. The issue gained 2 points to close at 5-3/16

Medical Glove Accelerated Aging Tests Acceptable For Expiration Dating

Accelerated aging tests in support of medical glove expiration dating are acceptable for a two-year period, FDA says in a draft guidance released Nov. 16.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel